Organogenesis Holdings (ORGO) said late Monday the independent data monitoring committee for its second phase 3 trial of ReNu to manage symptoms related to knee osteoarthritis recommended that the study proceed without modification and without increase to the sample size.
The committee also found the safety data to be consistent with the known safety profile for ReNu, the company said.
The 594-patient trial involves the ReNu amniotic suspension allograft to treat moderate to severe symptomatic knee osteoarthritis, a degenerative joint disease
The company's shares were up more than 5% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.